Skip to content
Peptigraph home

PT-141 Half-Life: How Long It Stays in Your System

How long PT-141 stays in the body, how that shapes dosing frequency, and what is known about drug testing.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureMelanocortin agonistUpdated
Half-life
approximately 2.7 hours (range 1.9-4.0 h)
subcutaneous, in people · FDA label (Vyleesi)
Dosing interval
Varies by study
as used in studies
WADA
Not listed
2026 Prohibited List
Detection window
Not found
None reported as of 2 Oct 2026

PT-141 half-life

A half-life depends on the route (under the skin, into a vein, by mouth or nasal spray) and the species it was measured in, so we report each value with its route and source.

PT-141 half-life by route
RouteHalf-lifeMeasured inSource
subcutaneousapproximately 2.7 hours (range 1.9-4.0 h)PeopleFDA label (Vyleesi)
intranasalmean t1/2 1.85 to 2.09 hPeopleInternational journal of impotence research 2004, PMID 14963471
As labelledapproximately 2.7 hours (range 1.9-4.0 h), single subcutaneous dosePeopleFDA label (Vyleesi)

What half-life means

Half-life is the time it takes for the amount of a drug in the blood to fall by half. After one half-life, about 50% is left; after two, about 25%; after four to five, only a few percent remain.

  • A long half-life lets a drug be dosed less often, for example once a week.
  • A short half-life means levels rise and fall quickly, which is why some peptides are given daily or more often.
  • Effects can outlast blood levels, so half-life alone does not tell you how long a drug works.

What it means for dosing frequency

Dosing intervals used in published studies of PT-141:

Changing the interval changes how much drug builds up between doses, so it is not a free choice.

Drug tests and sport

Not on the WADA Prohibited List

PT-141 (bremelanotide) is not named on the list and is FDA-approved (Vyleesi), so S0 does not apply. It does not fit the named S2 subclasses.

Anti-doping labs use tests built for specific substances. Whether a given test detects PT-141, and for how long, is not reported in the anti-doping literature we checked (as of 2 Oct 2026).

Subcutaneous, from the Vyleesi label

The Vyleesi label gives a mean terminal half-life for bremelanotide of approximately 2.7 hours, with a range of 1.9-4.0 hours after a single subcutaneous administration.[2]

Five half-lives is 9.5 to 20 hours across the label range, and 13.5 hours at 2.7 hours.

Calculated from typical half life 2.7 hours, after 1 half-lives (2.7 hours) 50.0% of the original amount, after 3 half-lives (8.1 hours) 12.5% of the original amount, after 5 half-lives (13.5 hours) 3.1% of the original amount; range low h 5 x 1.9 = 9.5; range high h 5 x 4.0 = 20. Formula: elapsed = n x half-life; remaining = 0.5^n

Intranasal, from an older trial

In a placebo-controlled intranasal trial in healthy males, mean t1/2 ranged from 1.85 to 2.09 h, shorter than the subcutaneous label figure.[3]

Regulatory note

Only the subcutaneous autoinjector is FDA-approved, as Vyleesi, so intranasal figures come from trials, not a label.[8]

WADA does not name PT-141; the S0 catch-all it does contain covers substances with no current approval, and Vyleesi is FDA-approved.[1]

Common questions

How long does PT-141 stay in your system?

Its reported half-life is approximately 2.7 hours (range 1.9-4.0 h) (subcutaneous); mean t1/2 1.85 to 2.09 h (intranasal). Most of a dose is gone after about four to five half-lives.

What is the half-life of PT-141?

The label says approximately 2.7 hours after a single subcutaneous dose.[2]

Is PT-141 on the WADA prohibited list?

No, it is not listed. PT-141 (bremelanotide) is not named on the list and is FDA-approved (Vyleesi), so S0 does not apply. It does not fit the named S2 subclasses.

More on PT-141

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2These highlights do not include all the information needed to use VYLEESI ® safely and effectively. See full prescribing information for VYLEESI VYLEESI (bremelanotide injection), for subcutaneous use Initial U.S. Approval: 2019FDA label (Vyleesi), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.International journal of impotence research · 2004PMID 14963471Accessed 2 Oct 2026
  4. 4Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.Journal of women's health (2002) · 2022PMID 35230162Accessed 2 Oct 2026
  5. 5Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.Obstetrics and gynecology · 2019PMID 31599840Accessed 2 Oct 2026
  6. 6Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.Clinical therapeutics · 2017PMID 28189361Accessed 2 Oct 2026
  7. 7Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.Women's health (London, England) · 2016PMID 27181790Accessed 2 Oct 2026
  8. 8Drugs@FDA (openFDA) search: active ingredient "bremelanotide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.